Cost‐effectiveness of second‐line empagliflozin versus liraglutide for type 2 diabetes in the United States

AIM: To estimate the cost‐effectiveness of sequential use of the sodium‐glucose co‐transporter‐2 inhibitor empagliflozin and glucagon‐like peptide‐1 receptor agonist liraglutide after metformin in patients with type 2 diabetes (T2D) from the US payer perspective. MATERIALS AND METHODS: An economic s...

Descripción completa

Detalles Bibliográficos
Autores principales: Reifsnider, Odette S., Pimple, Pratik, Brand, Sarah, Bergrath Washington, Evelien, Shetty, Sharash, Desai, Nihar R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305296/
https://www.ncbi.nlm.nih.gov/pubmed/34910356
http://dx.doi.org/10.1111/dom.14625

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305296/
https://www.ncbi.nlm.nih.gov/pubmed/34910356
http://dx.doi.org/10.1111/dom.14625

Ejemplares similares